Compare Jabil Inc (JBL) vs Johnson & Johnson (JNJ) Price & Performance

JBL trades at $305.91, up 1.63% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 50% analyst buy ratings and a $448.29 consensus price target, representing 46% upside potential. Recent news highlights AI infrastructure growth and new logistics hub expansion in Penang, while technical indicators show oversold conditions with RSI at 17.67.

The outlook remains positive with AI-driven revenue growth accelerating, though valuation at 38.29 P/E appears stretched. Key risks include competitive pressures in EMS sector and execution challenges in scaling AI manufacturing capacity. The stock offers growth exposure to AI infrastructure boom but requires monitoring of margin sustainability.

Johnson & Johnson (JNJ) trades at $250.61, down 0.96% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $2.90 versus $2.84 expected, and revenue growth of 6.6% year-over-year. The stock shows robust profitability with a net income margin of 21.48% and ROE of 26.42%, supported by consistent dividend payments including the recent $1.34 per share declared for H1-2026.

JNJ presents a favorable investment case with analyst consensus price target of $279.33 implying ~11% upside, though rising debt-to-asset ratio to 24.06% in 2025 and volatile cash flow trends pose risks. The healthcare giant's diversified portfolio and raised full-year guidance underpin long-term stability, but investors should monitor execution amid competitive and regulatory pressures.